Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 17/20 | 0.60 |
| ▸ | CHRM3 | P20309 | 17/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1246785 | 0.85 | CHRM2 (0.59) | CHRM2CHRM3 | |
| SCHEMBL1246163 | 0.84 | CHRM3 (0.67) | CHRM2CHRM3 | |
| SCHEMBL1247198 | 0.82 | CHRM2 (0.70) | CHRM2CHRM3 | |
| SCHEMBL1246700 | 0.81 | CHRM3 (0.63) | CHRM2CHRM3 | |
| Trifluoroacetic Acid SCHEMBL6524158 | 0.81 | ADRB2 (0.48) | CHRM2CHRM3 | |
| SCHEMBL1246858 | 0.80 | CHRM2 (0.64) | CHRM2CHRM3GAA | |
| Trifluoroacetic Acid SCHEMBL1246818 | 0.80 | CHRM2 (0.62) | CHRM2CHRM3GAA | |
| SCHEMBL1245985 | 0.80 | CHRM2 (0.66) | CHRM2CHRM3 | |
| Trifluoroacetic Acid SCHEMBL1244919 | 0.80 | CHRM2 (0.64) | CHRM2CHRM3 | |
| SCHEMBL1244891 | 0.80 | CHRM3 (0.60) | CHRM2CHRM3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459572-A2 | SPIROCYCLIC AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011012896-A2 | COMPOUNDS - 801 | ASTRAZENECA AB (SE) | 2011-02-03 | — | — | WO | disclosed |